Vesigen Therapeutics, Inc.

📍 Cambridge, United States👥 20 employees💰 Last funded Aug 2023
Biotechnology Research🌐 vesigen.com
Website LinkedIn
Vesigen is developing groundbreaking therapeutic products directed to intracellular targets using a scalable and extracellular vesicle delivery technology. Our patented technology, called ARMMs (ARRDC1 Mediated Microvesicles), enables us to deliver a wide range of payloads, including RNAs (mRNA, shRNA, ribozymes), proteins (signaling proteins, enzymes, antibody fragments), and editing complexes (Cas9/gRNA) directly into the cytoplasm of target cells, expanding the universe of druggable targets. Our team is committed to leveraging ARMMs technology to enable new therapies and address currently unmet medical needs.
4
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
3
Switzerland
1
Investor activity2020–2023 · investors recorded per year
2020320231
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Vesigen Therapeutics, Inc.?
Vesigen Therapeutics, Inc. has 4 investors on record on gritt.io.
When did Vesigen Therapeutics, Inc. last raise funding?
The most recent investment in Vesigen Therapeutics, Inc. recorded on gritt.io was in August 2023.
What industry is Vesigen Therapeutics, Inc. in?
Vesigen Therapeutics, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Vesigen Therapeutics, Inc. based?
Vesigen Therapeutics, Inc. is headquartered in Cambridge, United States.